Research Topic

Diagnosis and Treatment of Hepatitis C Infection: The Settled and the Unsettled

About this Research Topic

Chronic hepatitis C virus (HCV) infection is one of the leading causes of liver diseases, presenting a heavy burden to global health systems. Fortunately, we are now in the era of potent pan-genotypic direct antiviral agents (DAAs), and we will embrace the HCV elimination era shortly. However, there are some unaddressed real-world issues. For example, many chronic hepatitis C patients, especially those in resource-limited areas and those at a high risk of infection have no access to screening, diagnosis, and treatment. Hepatitis C micro-elimination and cascade of care are in great needs. On the other hand, although the Sustained Virological Response (SVR) is very high, we must face the difficult-to-treat chronic hepatitis C patients, even though some of them have been treated with the potent DAAs. The mechanism and solution should be investigated. Moreover, the long-term outcome of the DAA-cured hepatitis C patients is still worth following up.

In this Research Topic, we aim to provide perspectives and evidence relating to the cost-effective real-world approaches of screening HCV infection, the mechanisms and treatment solutions for the difficult-to-treat chronic hepatitis C patients, and the sensitive surveillance strategies for the patients achieving SVR after DAA therapy.

We welcome submissions of Original Research, Review, Systematic Review, Mini Review, Meta-analysis, Case Report and Perspective articles on the sub-topics below:

· Finding the cost-effective diagnostic strategies to link the potential HCV infectors to cure: experiences from different populations and settings
· The role of the point-of-care anti-HCV and HCV core antigen testing for screening and treatment monitoring
· Difficult-to-treat chronic hepatitis C in the era of potent direct antiviral agents (DAAs): mechanism and solution
· The role of the resistance associated substitution (RAS) in the DAA treatment failure scenarios
· Liver cirrhosis and hepatocellular carcinoma surveillance in the coming post-DAA era


Keywords: Hepatitis C virus, Chronic hepatitis C, Diagnostic strategy, Direct antiviral agents, Elimination


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Chronic hepatitis C virus (HCV) infection is one of the leading causes of liver diseases, presenting a heavy burden to global health systems. Fortunately, we are now in the era of potent pan-genotypic direct antiviral agents (DAAs), and we will embrace the HCV elimination era shortly. However, there are some unaddressed real-world issues. For example, many chronic hepatitis C patients, especially those in resource-limited areas and those at a high risk of infection have no access to screening, diagnosis, and treatment. Hepatitis C micro-elimination and cascade of care are in great needs. On the other hand, although the Sustained Virological Response (SVR) is very high, we must face the difficult-to-treat chronic hepatitis C patients, even though some of them have been treated with the potent DAAs. The mechanism and solution should be investigated. Moreover, the long-term outcome of the DAA-cured hepatitis C patients is still worth following up.

In this Research Topic, we aim to provide perspectives and evidence relating to the cost-effective real-world approaches of screening HCV infection, the mechanisms and treatment solutions for the difficult-to-treat chronic hepatitis C patients, and the sensitive surveillance strategies for the patients achieving SVR after DAA therapy.

We welcome submissions of Original Research, Review, Systematic Review, Mini Review, Meta-analysis, Case Report and Perspective articles on the sub-topics below:

· Finding the cost-effective diagnostic strategies to link the potential HCV infectors to cure: experiences from different populations and settings
· The role of the point-of-care anti-HCV and HCV core antigen testing for screening and treatment monitoring
· Difficult-to-treat chronic hepatitis C in the era of potent direct antiviral agents (DAAs): mechanism and solution
· The role of the resistance associated substitution (RAS) in the DAA treatment failure scenarios
· Liver cirrhosis and hepatocellular carcinoma surveillance in the coming post-DAA era


Keywords: Hepatitis C virus, Chronic hepatitis C, Diagnostic strategy, Direct antiviral agents, Elimination


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

22 May 2021 Abstract
19 September 2021 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

22 May 2021 Abstract
19 September 2021 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..